arrow
L

Lorenzo Algarra

complejo hospitalario universitario de albacete
H指数:11
被引数:596

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Measurable residual disease assessment as an early end point of treatment efficacy in acute myeloid leukemia: a multinational PETHEMA study of 2623 patients treated with intensive therapy

可测量残留病灶评估作为急性髓系白血病治疗早期疗效终点:一项多国PETHEMA研究,纳入2623例接受强化疗的患者

Leukemia
IF13.4
2026-10-080
PRE
Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study
2026-09-010
OAAI
Impact of molecular profiling in patients with acute myeloid leukemia undergoing allogeneic transplantation in first remission: a study by the PETHEMA group

急性髓系白血病患者在首次缓解期接受 allo 移植时分子分型的临床影响:PETHEMA 小组的研究

2026-05-070
PRE
Healthcare Resource Utilization and Treatment Costs for Blastic Plasmacytoid Dendritic Celleoplasm: A PETHEMA Study

血液病性浆细胞样树突状细胞肿瘤的医疗资源利用和治疗成本:一项PETHEMA研究

Cancers
IF4.4
2026-03-030
OAAI
Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World Study

老年(≥60岁)FLT3突变急性髓系白血病患者采用含或不含Midostaurin的强化化疗:一项FILO-DATAML-PETHEMA真实世界研究

2026-02-110
OAAI
Interlaboratory cross validation of acute myeloid leukemia fusion genes and mutational targets detected by PCR: Performance of PETHEMA central laboratories

实验室间交叉验证由PCR检测到的急性髓系白血病融合基因和突变靶点:PETHEMA中心实验室的表现

2025-12-010
PRE
Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry

自体干细胞移植与强化疗巩固治疗急性髓系白血病患者的长期获益:一项来自PETHEMA AML登记研究的倾向性评分匹配分析

Leukemia
IF13.4
2025-09-010
OAAI
Autologous or Allogeneic Hematopoietic Stem Cell Transplantation as Front-Line Treatment for Adult Secondary Acute Myeloid Leukemia Patients: The PETHEMA Registry Experience

自体或异基因造血干细胞移植作为成人继发性急性髓系白血病患者的首线治疗:PETHEMA登记研究经验

2025-02-010
PRE
Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study

低甲基化药物引起的继发性急性髓细胞性白血病的治疗模式和结果: PETHEMA注册研究

CANCER
IF5.1
2025-01-020
PRE
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry
CANCER
IF5.1
2024-06-191
PRE
Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?
2024-06-170
PRE
Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry
2024-04-180
OAAI
Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience
2023-12-192
OAAI
Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry
2023-05-184
OAAI
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
2023-05-128
OAAI
The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients
2022-11-245
OAAI
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study
2022-02-1737
OAAI
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens
2021-10-2016
OAAI
Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study

在具有中等细胞遗传学风险的急性髓系白血病的分子分层患者中,自体与同种异体干细胞移植后的长期结果: 一项PETHEMA研究

2021-04-018
OAAI